Avandia litigation is expected to reach thousands more following crucial information indicating that the popular diabetes drug is twice as likely to lead to heart failure in diabetes patients.
Attorney Bryan Aylstock, co-lead counsel in the In re: Avandia MDL nationwide litigation, has recently come back from Philadelphia where he has participated in the depositions of individuals who were significant figures within the scientific and regulatory departments at GlaxoSmithKline during the pre-approval and post-approval and marketing of the diabetes drug Avandia. Additionally, depositions were taken of other top figures at Glaxo in London, England. As a result of these depositions and Mr. Aylstock’s team of document analysts who have assisted in the review of information turned over to the plaintiff’s discovery committee, the Avandia litigation is appearing to mimick the Vioxx experience more and more. Merck’s Vioxx was under fire for causing heart attacks and strokes. Studies have shown an increased risk of heart attacks, strokes and congestive heart failure in patients taking Avandia. The Vioxx litigation resulted in a settlement that was reported to be approximately $4.8 Billion Dollars.